Immunotherapy for transplantation-associated viral infections

被引：50
作者：
Roddie, Claire [1 ,2 ]
Peggs, Karl S. [1 ,2 ]
机构：
[1] UCL, Canc Inst, Dept Haematol, Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England
[2] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England
来源：
JOURNAL OF CLINICAL INVESTIGATION | 2017年 / 127卷 / 07期
基金：
英国医学研究理事会;
关键词：
STEM-CELL TRANSPLANTATION; EPSTEIN-BARR-VIRUS; CYTOTOXIC T-LYMPHOCYTES; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PREVENT CYTOMEGALOVIRUS DISEASE; SOLID-ORGAN TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; HLA-PEPTIDE TETRAMERS; ADOPTIVE IMMUNOTHERAPY;
D O I：
10.1172/JCI90599
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections following allogeneic hematopoietic stem cell transplantation (HSCT) are a major cause of morbidity and mortality. Early clinical trials demonstrate that adoptive transfer of donor-derived virus-specific T cells to restore virus-specific immunity is an effective strategy to control CMV and EBV infection after HSCT, conferring protection in 70%-90% of patients. The field has evolved rapidly to develop solutions to some of the manufacturing challenges identified in early clinical studies, such as prolonged in vitro culture, optimization of the purity of the virus-specific T cell product, the potential limitations of targeting a single viral antigen, and how to manage the patient with a virus-naive donor. This Review both discusses the seminal early studies and explores cutting-edge novel technologies that broaden the feasibility of and the scope for delivering virus-specific T cells to patients after HSCT.
引用
收藏
页码：2513 / 2522
页数：10
相关论文
共 93 条
[21]   Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy [J].
Fujita, Yuriko ;
Leen, Ann M. ;
Sun, Jiali ;
Nakazawa, Yozo ;
Yvon, Eric ;
Heslop, Helen E. ;
Brenner, Malcohn K. ;
Rooney, Cliona M. .
JOURNAL OF IMMUNOTHERAPY, 2008, 31 (07) :665-674
[22]  
Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480
[23]   Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant [J].
Gerdemann, Ulrike ;
Katari, Usha L. ;
Papadopoulou, Anastasia ;
Keirnan, Jacqueline M. ;
Craddock, John A. ;
Liu, Hao ;
Martinez, Caridad A. ;
Kennedy-Nasser, Alana ;
Leung, Kathryn S. ;
Gottschalk, Stephen M. ;
Krance, Robert A. ;
Brenner, Malcolm K. ;
Rooney, Cliona M. ;
Heslop, Helen E. ;
Leen, Ann M. .
MOLECULAR THERAPY, 2013, 21 (11) :2113-2121
[24]   Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections [J].
Gerdemann, Ulrike ;
Keirnan, Jacqueline M. ;
Katari, Usha L. ;
Yanagisawa, Ryu ;
Christin, Anne S. ;
Huye, Leslie E. ;
Perna, Serena K. ;
Ennamuri, Sravya ;
Gottschalk, Stephen ;
Brenner, Malcolm K. ;
Heslop, Helen E. ;
Rooney, Cliona M. ;
Leen, Ann M. .
MOLECULAR THERAPY, 2012, 20 (08) :1622-1632
[25]   Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host [J].
Gerdemann, Ulrike ;
Christin, Anne S. ;
Vera, Juan F. ;
Ramos, Carlos A. ;
Fujita, Yuriko ;
Liu, Hao ;
Dilloo, Dagmar ;
Heslop, Helen E. ;
Brenner, Malcolm K. ;
Rooney, Cliona M. ;
Leen, Ann M. .
MOLECULAR THERAPY, 2009, 17 (09) :1616-1625
[26]   GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT [J].
GOODRICH, JM ;
BOWDEN, RA ;
FISHER, L ;
KELLER, C ;
SCHOCH, G ;
MEYERS, JD .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :173-178
[27]   EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
GOODRICH, JM ;
MORI, M ;
GLEAVES, CA ;
DUMOND, C ;
CAYS, M ;
EBELING, DF ;
BUHLES, WC ;
DEARMOND, B ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) :1601-1607
[28]   Adoptive T-Cell Immunotherapy [J].
Gottschalk, Stephen ;
Rooney, Cliona M. .
EPSTEIN BARR VIRUS, VOL 2: ONE HERPES VIRUS: MANY DISEASES, 2015, 391 :427-454
[29]   Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection [J].
Gratama, JW ;
van Esser, JWJ ;
Lamers, CHJ ;
Toumay, C ;
Löwenberg, B ;
Bolhuis, RLH ;
Cornelissen, JJ .
BLOOD, 2001, 98 (05) :1358-1364
[30]   Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease:: prophylactic infusion of EBV-specific cytotoxic T cells [J].
Gustafsson, Å ;
Levitsky, V ;
Zou, JZ ;
Frisan, T ;
Dalianis, T ;
Ljungman, P ;
Ringden, O ;
Winiarski, J ;
Ernberg, I ;
Masucci, MG .
BLOOD, 2000, 95 (03) :807-814
12345678910